Application
A.Western blot analysis on 293T cell lysates using anti-Phospho-GSK3 beta (pS9) RabMAb (Cat. #AJ1334e), 1:20,000 dilution. Cells were either (A) untreated (B) treated with Calyculin A.Application
B. Immunohistochemical analysis of paraffin-embedded human ovarian carcinoma using Phospho-specific anti-GSK3 beta (pS9) RabMAb (Cat. #AJ1334e).| Product Name | GSK3 beta Antibody Phospho (pS9) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | GSK3B, Glycogen synthase kinase-3 beta |
| Modification | p-S9 |
| Clonality | Monoclonal |
|---|---|
| Clone Number | EPR2286Y |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:10000~20000 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | GSK3B Glycogen synthase kinase-3 beta |
|---|---|
| Molecular Weight(MW) | 46744 Da |
| Function | Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity Phosphorylates ZC3HAV1 which enhances its antiviral activity Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation |
| Tissue Specificity | Expressed in testis, thymus, prostate and ovary and weakly expressed in lung, brain and kidney |
| Cellular Localization | Cytoplasm. Nucleus. Cell membrane. Note=The phosphorylated form shows localization to cytoplasm and cell membrane. The MEMO1-RHOA-DIAPH1 signaling pathway controls localization of the phosphorylated form to the cell membrane |
| Entrez Gene | 2932 |
|---|
Application
A.Western blot analysis on 293T cell lysates using anti-Phospho-GSK3 beta (pS9) RabMAb (Cat. #AJ1334e), 1:20,000 dilution. Cells were either (A) untreated (B) treated with Calyculin A.
Application
B. Immunohistochemical analysis of paraffin-embedded human ovarian carcinoma using Phospho-specific anti-GSK3 beta (pS9) RabMAb (Cat. #AJ1334e).| Application Notes | WB:1:10000~20000 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
